Latest Breaking News On - Summit healthcare acquisition corp - Page 1 : comparemela.com

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

Total revenues increase by 36.3% year-over-year; gross margin improves to 77.7%; balance sheet remains robust Company s PIKA rabies vaccine approved for Phase III clinical trials in Singapore, the.

Hong kongUnited statesRobin yangDavid shaoAlyssa liPrnewswire ys biopharma co ltdExchange rate informationDevelopment expensesSource ys biopharma co ltdSummit healthcare acquisition corpRsys groupSecurities exchangeFiscal yearSummit healthcare acquisitionNasdaq capital marketStates toll free

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

/PRNewswire/ YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing,.

Hong kongUnited statesDavid shaoAlyssa liRobin yangSummit healthcare acquisition corpPrnewswire ys biopharma co ltdDevelopment expensesExchange rate informationSource ys biopharma co ltdSecurities exchangeRsys groupFiscal yearSummit healthcare acquisitionNasdaq capital marketStates toll free

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023

YS Biopharma Announces Financial Results for Fiscal Year 2023 Ended March 31, 2023
sina.com.hk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.hk Daily Mail and Mail on Sunday newspapers.

United statesHong kongRobin yangAlyssa liDavid shaoDevelopment expensesExchange rate informationSummit healthcare acquisition corpSecurities exchangeRsys groupYs biopharma co ltdFiscal yearSummit healthcare acquisitionNasdaq capital marketStates toll freeChina toll free

YS INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages YS Biopharma Co , Ltd f/k/a Summit Healthcare Acquisition Corp Investors to Inquire About Securities Class Action Investigation – YS, SMIH

YS INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages YS Biopharma Co , Ltd f/k/a Summit Healthcare Acquisition Corp Investors to Inquire About Securities Class Action Investigation – YS, SMIH
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesLaurence rosenPhillip kimSecurities class action servicesSummit healthcare acquisition corpRosen law firmYs biopharma co ltdChinese companySummit healthcare acquisitionLaw firmClass action services

YS INVESTOR NEWS: ROSEN, SKILLED INVESTOR COUNSEL, Encourages YS Biopharma Co , Ltd f/k/a Summit Healthcare Acquisition Corp Investors to Inquire About Securities Class Action Investigation – YS, SMIH

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) WHY: Rosen Law Firm, a global investor rights law firm, continues to in.

New yorkUnited statesPhillip kimLaurence rosenRosen law firmSecurities class action servicesSummit healthcare acquisition corpYs biopharma co ltdChinese companySummit healthcare acquisitionLaw firmClass action servicesSina com hkHong kong